Prespecified secondary analysis of FINEARTS-HF (5,986 patients with HFmrEF/HFpEF): finerenone's effect on total HF events and CV death was consistent across eGFR-based dosing strata (high-dose RR 0.77; low-dose RR 0.87; P interaction 0.34), with consistent safety.
Secondary analysisn = 5,986
Chimura et al. Efficacy and Safety of the Kidney Function-Based Finerenone Dosing Strategy Used in FINEARTS-HF